Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
Celsion‘s immunotherapy candidate, GEN-1, has received fast track designation from the U.S. Food and Drug Administration (FDA) for advanced ovarian cancer. ... Read more
She ROCKS, an organization working for earlier diagnosis and better treatments for ovarian cancer, raised $100,000 through recent virtual luncheon fundraisers ... Read more
InVivo Analytics has received $1.7 million to develop and commercialize its next-generation fluorescence imaging device, called InVivoFLUOR, for 3D monitoring of ... Read more
Ultimovacs will test its experimental cancer vaccine, UV1, as part of a triple-combination therapy for women with relapsed ovarian cancer who ... Read more
Combining the experimental vaccine galinpepimut-S (GPS) with the immune checkpoint inhibitor Keytruda (pembrolizumab) induces promising responses in people with metastatic ovarian cancer ... Read more
IMV‘s immunotherapy DPX-Survivac plus low-dose chemotherapy continues to show sustained benefits in people with heavily treated advanced ovarian cancer, with some benefits ... Read more
Updated interim data from a Phase 1 clinical trial continues to support the safety and anti-tumor activity of Sutro Biopharma’s STRO-002 for heavily ... Read more
The first two patients have been randomized in Phase 2 of the OVATION 2 trial testing the immunotherapy candidate GEN-1 in newly diagnosed ... Read more
